Anti-angiogenesis treatment improves hearing in some NF2 patients

Treatment with the angiogenesis inhibitor bevacizumab improved hearing and alleviated other symptoms in patients with neurofibromatosis type 2 (NF2). In a paper to appear in the 23 July New England Journal of Medicine, which is receiving early online release, researchers from Massachusetts General Hospital (MGH) report that bevacizumab treatment successfully shrank characteristic tumours in a small group of NF2 patients, the first reported successful NF2 treatment not involving surgery or radiation...

Read the whole article on

More from